Specifications Manual for Joint Commission National Quality Measures (v2020B2)
Posted: 9/2/2020
Home » Reason for Not Administering Nimodipine Treatment

Release Notes:
Data Element
Version 2020B2

Name:Reason for Not Administering Nimodipine Treatment
Collected For: CSTK-06
Definition:Reason for not administering nimodipine treatment:
  • Nimodipine allergy
  • Non-aneurysmal subarachnoid hemorrhage (SAH)
  • Reversible cerebral vasoconstriction syndrome
  • Cerebral amyloid angiopathy
  • Other reasons documented by physician/advanced practice nurse/physician assistant (physician/APN/PA) or pharmacist

Nimodipine inhibits calcium transport into vascular smooth muscle cells, thereby preventing or limiting cerebral vasospasm.
Question:Is there documentation by a physician/APN/PA or pharmacist in the medical record of a reason for not administering nimodipine treatment?
Format:
Length:1
Type:Alphanumeric
Occurs:1
Allowable Values:

Y (Yes) There is documentation of a reason for not administering nimodipine treatment.

N (No) There is no documentation of a reason for not administering nimodipine treatment, OR unable to determine from medical record documentation.
Notes for Abstraction:
  • Reasons for not administering nimodipine must be documented by the physician/APN/PA or pharmacist within 24 hours of hospital arrival. It is not necessary to review documentation outside of this timeframe.
  • The following are acceptable as stand-alone reasons for not administering nimodipine treatment – Nimodipine linkage is not needed:
    • Non-aneurysmal subarachnoid hemorrhage (SAH)
    • Reversible cerebral vasoconstriction syndrome
    • Cerebral amyloid angiopathy
  • If reasons are not mentioned in the context of nimodipine treatment, do not make inferences (e.g., do not assume that nimodipine was not administered because of hypotension unless documentation explicitly states so.)
    • Reasons must be explicitly documented (e.g., “BP 80/40 — No nimodipine.”)
    • Physician/APN/PA or pharmacist documentation of a hold on nimodipine or discontinuation of nimodipine that occurs within the first 24 hours of hospital arrival constitutes a “clearly implied” reason for not administering nimodipine treatment. A hold/discontinuation of all P.O. medications counts if nimodipine (i.e., Nimotop, Nymalize) was on order at the time of the notation.
      EXCEPTION:
      Documentation of a conditional hold or discontinuation of nimodipine (e.g., “Hold nimodipine if SBP < 100 mm/Hg”, “Stop nimodipine if AST > 50 IU/L”.
  • When conflicting information is documented in the medical record, select “Yes”.
  • Documentation that the patient is NPO or has a nasogastric tube (NGT) without mention that nimodipine should not be administered is insufficient. Do not infer that nimodipine is not needed unless explicitly documented.
    • Physician orders for “NPO except medications” does not count as a reason for not administering nimodipine, select “No”.
Suggested Data Sources:
  • Emergency department record
  • Nursing flow sheet
  • Progress notes
  • Medication administration record (MAR)
  • Medication reconciliation form
Additional Notes: Excluded Data Sources:
  • Any documentation dated/timed later than 24 hours after hospital arrival.
Guidelines for Abstraction:
Inclusion Exclusion
  • Patient/family refusal
None

Reason for Not Administering Nimodipine Treatment
CPT® only copyright 2019 American Medical Association. All rights reserved.
Specifications Manual for Joint Commission National Quality Measures (v2020B2)
Discharges 07-01-20 (3Q20) through 12-31-20 (4Q20)

LICENSE FOR USE OF CURRENT PROCEDURAL TERMINOLOGY, FOURTH EDITION (“CPT®”)

CPT® only copyright 2019 American Medical Association. All rights reserved. CPT® is a registered trademark of the American Medical Association.

You, your employees and agents are authorized to use CPT® only as contained in The Joint Commission performance measures solely for your own personal use in directly participating in healthcare programs administered by The Joint Commission. You acknowledge that the American Medical Association (“AMA”) holds all copyright, trademark and other rights in CPT®.

Any use not authorized herein is prohibited, including by way of illustration and not by way of limitation, making copies of CPT® for resale and/or license, transferring copies of CPT® to any party not bound by this Agreement, creating any modified or derivative work of CPT®, or making any commercial use of CPT®. License to use CPT® for any use not authorized herein must be obtained through the American Medical Association, Intellectual Property Services, AMA Plaza, 330 North Wabash Avenue, Suite 39300, Chicago, Illinois 60611-5885. Applications are available at the American Medical Association Web site, www.ama- assn.org/go/cpt.

U.S. Government Rights This product includes CPT® which is commercial technical data, which was developed exclusively at private expense by the American Medical Association, 330 North Wabash Avenue, Chicago, Illinois 60611. The American Medical Association does not agree to license CPT® to the Federal Government based on the license in FAR 52.227-14 (Data Rights - General) and DFARS 252.227-7015 (Technical Data - Commercial Items) or any other license provision. The American Medical Association reserves all rights to approve any license with any Federal agency.

Disclaimer of Warranties and Liabilities. CPT® is provided “as is” without warranty of any kind, either expressed or implied, including but not limited to the implied warranties of merchantability and fitness for a particular purpose. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT®, and the (AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The responsibility for the content of this product is with The Joint Commission, and no endorsement by the AMA is intended or implied. The AMA disclaims responsibility for any consequences or liability attributable to or related to any use, non-use, or interpretation of information contained or not contained in this product.

This Agreement will terminate upon notice if you violate its terms. The AMA is a third party beneficiary to this Agreement.

Should the foregoing terms and conditions be acceptable to you, please indicate your agreement and acceptance by clicking below on the button labeled “accept”.

^